RE-EVALUATING THE IMPACT OF INVASIVE ASPERGILLOSIS ON THE PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS
(Abstract release date: 05/19/16)
EHA Library. Ledoux M. 06/09/16; 132735; E1186
Disclosure(s): Research support from Pfizer
Honoraria and consultant work from Gilead
Dr. Marie-Pierre Ledoux
Contributions
Contributions
Abstract
Abstract: E1186
Type: Eposter Presentation
Background
Invasive aspergillosis (IA) is a common complication of neutropenic and immunocompromised status occuring during acute myeloid leukemia (AML) management. Its prognosis has long been dismal, causing an important additional mortality in hematology patients. However, both diagnostic procedures and therapeutics have much improved, through galactomannan dosing, high resolution CT-scan and voriconazole avaibility.
Aims
We intended to assess frequency and prognostic impact of IA in a recent cohort of patients receiving high dose chemotherapy for AML.
Methods
We have therefore conducted a monocentric retrospective observational study on all consecutive patients diagnosed with an AML between 2008 and 2012 in Strasbourg University Hospital.
Results
Among 285 patients diagnosed with AML between 2008 and 2012 in our hospital, 154 received an intensive chemotherapy, with at least one induction course. Among them, 46 patients (29,9%) have been diagnosed with IA (2 proven IA, 25 probable IA, 19 possible IA). Twenty-eight (18,2%) of these infections occured following the first induction course (2 proven IA, 17 probable IA, 9 possible IA). Both groups of patients, whether they had an IA or not, had similar hematological prognosis as assessed by ELN scoring. Almost all IA patients (44, i.e. 96%) received voriconazole as a treatment. At the closing of our analysis, 17 patients diagnosed with an IA were still alive, with a follow-up ranging from 32 months to 93 months (median 64 months). The overall survival (OS) analysis of these patients showed no significant difference compared to patients without IA (p=0.94). Five-year survival of the two groups was respectively 40,6% and 41%.
Conclusion
With an incidence of IA close to recent data concerning patients treated for AML, our monocentric retrospective study on long-term survival of AML and IA patients shows no significant difference in terms of overall survival. These encouraging results shall now be confirmed on a larger cohort to conclude that the impact of IA on the prognosis of AML patients has been controlled in the era of diagnostic and therapeutic improvement.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Aspergillus
Type: Eposter Presentation
Background
Invasive aspergillosis (IA) is a common complication of neutropenic and immunocompromised status occuring during acute myeloid leukemia (AML) management. Its prognosis has long been dismal, causing an important additional mortality in hematology patients. However, both diagnostic procedures and therapeutics have much improved, through galactomannan dosing, high resolution CT-scan and voriconazole avaibility.
Aims
We intended to assess frequency and prognostic impact of IA in a recent cohort of patients receiving high dose chemotherapy for AML.
Methods
We have therefore conducted a monocentric retrospective observational study on all consecutive patients diagnosed with an AML between 2008 and 2012 in Strasbourg University Hospital.
Results
Among 285 patients diagnosed with AML between 2008 and 2012 in our hospital, 154 received an intensive chemotherapy, with at least one induction course. Among them, 46 patients (29,9%) have been diagnosed with IA (2 proven IA, 25 probable IA, 19 possible IA). Twenty-eight (18,2%) of these infections occured following the first induction course (2 proven IA, 17 probable IA, 9 possible IA). Both groups of patients, whether they had an IA or not, had similar hematological prognosis as assessed by ELN scoring. Almost all IA patients (44, i.e. 96%) received voriconazole as a treatment. At the closing of our analysis, 17 patients diagnosed with an IA were still alive, with a follow-up ranging from 32 months to 93 months (median 64 months). The overall survival (OS) analysis of these patients showed no significant difference compared to patients without IA (p=0.94). Five-year survival of the two groups was respectively 40,6% and 41%.
Conclusion
With an incidence of IA close to recent data concerning patients treated for AML, our monocentric retrospective study on long-term survival of AML and IA patients shows no significant difference in terms of overall survival. These encouraging results shall now be confirmed on a larger cohort to conclude that the impact of IA on the prognosis of AML patients has been controlled in the era of diagnostic and therapeutic improvement.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Aspergillus
Abstract: E1186
Type: Eposter Presentation
Background
Invasive aspergillosis (IA) is a common complication of neutropenic and immunocompromised status occuring during acute myeloid leukemia (AML) management. Its prognosis has long been dismal, causing an important additional mortality in hematology patients. However, both diagnostic procedures and therapeutics have much improved, through galactomannan dosing, high resolution CT-scan and voriconazole avaibility.
Aims
We intended to assess frequency and prognostic impact of IA in a recent cohort of patients receiving high dose chemotherapy for AML.
Methods
We have therefore conducted a monocentric retrospective observational study on all consecutive patients diagnosed with an AML between 2008 and 2012 in Strasbourg University Hospital.
Results
Among 285 patients diagnosed with AML between 2008 and 2012 in our hospital, 154 received an intensive chemotherapy, with at least one induction course. Among them, 46 patients (29,9%) have been diagnosed with IA (2 proven IA, 25 probable IA, 19 possible IA). Twenty-eight (18,2%) of these infections occured following the first induction course (2 proven IA, 17 probable IA, 9 possible IA). Both groups of patients, whether they had an IA or not, had similar hematological prognosis as assessed by ELN scoring. Almost all IA patients (44, i.e. 96%) received voriconazole as a treatment. At the closing of our analysis, 17 patients diagnosed with an IA were still alive, with a follow-up ranging from 32 months to 93 months (median 64 months). The overall survival (OS) analysis of these patients showed no significant difference compared to patients without IA (p=0.94). Five-year survival of the two groups was respectively 40,6% and 41%.
Conclusion
With an incidence of IA close to recent data concerning patients treated for AML, our monocentric retrospective study on long-term survival of AML and IA patients shows no significant difference in terms of overall survival. These encouraging results shall now be confirmed on a larger cohort to conclude that the impact of IA on the prognosis of AML patients has been controlled in the era of diagnostic and therapeutic improvement.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Aspergillus
Type: Eposter Presentation
Background
Invasive aspergillosis (IA) is a common complication of neutropenic and immunocompromised status occuring during acute myeloid leukemia (AML) management. Its prognosis has long been dismal, causing an important additional mortality in hematology patients. However, both diagnostic procedures and therapeutics have much improved, through galactomannan dosing, high resolution CT-scan and voriconazole avaibility.
Aims
We intended to assess frequency and prognostic impact of IA in a recent cohort of patients receiving high dose chemotherapy for AML.
Methods
We have therefore conducted a monocentric retrospective observational study on all consecutive patients diagnosed with an AML between 2008 and 2012 in Strasbourg University Hospital.
Results
Among 285 patients diagnosed with AML between 2008 and 2012 in our hospital, 154 received an intensive chemotherapy, with at least one induction course. Among them, 46 patients (29,9%) have been diagnosed with IA (2 proven IA, 25 probable IA, 19 possible IA). Twenty-eight (18,2%) of these infections occured following the first induction course (2 proven IA, 17 probable IA, 9 possible IA). Both groups of patients, whether they had an IA or not, had similar hematological prognosis as assessed by ELN scoring. Almost all IA patients (44, i.e. 96%) received voriconazole as a treatment. At the closing of our analysis, 17 patients diagnosed with an IA were still alive, with a follow-up ranging from 32 months to 93 months (median 64 months). The overall survival (OS) analysis of these patients showed no significant difference compared to patients without IA (p=0.94). Five-year survival of the two groups was respectively 40,6% and 41%.
Conclusion
With an incidence of IA close to recent data concerning patients treated for AML, our monocentric retrospective study on long-term survival of AML and IA patients shows no significant difference in terms of overall survival. These encouraging results shall now be confirmed on a larger cohort to conclude that the impact of IA on the prognosis of AML patients has been controlled in the era of diagnostic and therapeutic improvement.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Aspergillus
{{ help_message }}
{{filter}}